Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database

Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study

(2022) Yu Zhou et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes

(2022) Mohamed Sayed Zaazouee et al.   Diabetes & Metabolic Syndrome-Clinical Research & Reviews

Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS)

(2022) Jing Huang et al.   International Journal of Clinical Pharmacy

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system ( FAERS ) database

(2022) Yamin Shu et al.   Cancer Medicine

Cardiovascular complications of modern multiple myeloma therapy: A pharmacovigilance study

(2022) Zaki Al‐Yafeai et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system

(2022) Donald C. Moore et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline

(2021) Sheyu Li et al.   BMJ-British Medical Journal

Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance

(2021) Annamaria Mascolo et al.   DRUG SAFETY

IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045

(2021) Hong Sun et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)

(2021) N.E. Omar et al.   ESMO Open

Hematological toxicities in immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2019

(2020) Xiaofei Ye et al.   HEMATOLOGICAL ONCOLOGY

Gastrointestinal adverse events with insulin glargine/lixisenatide fixed‐ratio combination versus glucagon‐like peptide‐1 receptor agonist s in people with type 2 diabetes mellitus: A network meta‐analysis

(2020) Christopher K. Rayner et al.   DIABETES OBESITY & METABOLISM

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

(2020) Michael A. Nauck et al.   Molecular Metabolism

Semaglutide as a promising antiobesity drug

(2019) Georgios A. Christou et al.   Obesity Reviews

Gastrin secretion in normal subjects and diabetes patients is inhibited by glucagon-like peptide 1: a role in the gastric side effects of GLP-1-derived drugs?

(2019) Jens F. Rehfeld et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

An overview of GLP-1 agonists and recent cardiovascular outcomes trials

(2019) Kelsey H Sheahan et al.   POSTGRADUATE MEDICAL JOURNAL

GLP-1 and weight loss: unraveling the diverse neural circuitry

(2016) Scott E. Kanoski et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials

(2016) Karolin Bettge et al.   DIABETES OBESITY & METABOLISM

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports

(2016) Noha Abdel-Wahab et al.   PLoS One

Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

(2015) Feng Sun et al.   Diabetes Technology & Therapeutics

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies

(2014) L. Li et al.   BMJ-British Medical Journal

Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database

(2013) Jean-Luc Faillie et al.   ACTA DIABETOLOGICA

Elevated Amylase and Lipase Levels in Patients Using Glucagonlike Peptide-1 Receptor Agonists or Dipeptidyl-Peptidase-4 Inhibitors in the Outpatient Setting

(2012) Howard Lando et al.   Endocrine Practice